Objective: To determine whether thyroid hormone (free thyroxine (fT 4 )) rather than TSH is directly related to bone mineral density (BMD). Design: Cross-sectional population cohort study of peri-menopausal women. Methods: Of a sample of 6846 peri-menopausal Dutch women who participated in an osteoporosis-screening programme, a cohort of 2584 was randomly selected for the assessment of thyroid function (TSH, fT 4 and thyroid peroxidase antibodies (TPO-Abs)). TPO-Ab-positive women, with a previous history of thyroid dysfunction, overt thyroid disease, subclinical hypothyroidism, osteoporosis or bilateral oophorectomy and those receiving thyroid hormone or hormone replacement therapy were excluded. Of 1477 eligible women, 1426 had TSH and fT 4 within the reference range and 51 had low or undetectable serum TSH. BMD was measured at the lumbar spine and low BMD was defined as !0.937 g/cm 2 .
Introduction
Subclinical thyroid dysfunction is a biochemical disturbance in which the thyrotrophin (TSH) level is outside the reference range while 3,5,3 0 ,5 0 -L-tetraiodothyronine (thyroxine (T 4 )) levels lie within normal limits (1) . The concept of subclinical thyroid dysfunction has been subject to a prolonged debate and was discussed in a dedicated workshop at the International Thyroid Congress in 2010 (2) . A previous expert review concluded that there is little evidence to support an association between subclinical thyroid dysfunction and adverse clinical outcome, and no evidence to indicate clear benefit of treatment (1) . These conclusions were reinforced by Biondi & Cooper (3, 4) .
Although TSH stimulates T 4 secretion by thyroid follicular cells (5, 6) , it has only recently been accepted that the effects of the hypothalamic-pituitary-thyroid (HPT) axis on its end organs are ultimately related to levels of thyroid hormones and to the activities of the deiodinase enzymes that regulate the local concentration of 3, 5, 3 0 -L-triiodothyronine (T 3 ). Thus, T 4 is a pro-hormone of the biologically active T 3 (5, 6) . Furthermore, the HPT axis setpoint varies in a population to a much greater extent than in individuals (7) because, in an individual, it is largely genetically determined (8) . Thus, factors that control circulating thyroid status are likely to differ from those that determine thyroid hormone concentrations in individual tissues; TSH has an inverse logarithmic relationship to free T 4 (fT 4 ), and this is determined in the pituitary and hypothalamus, therefore the circulating TSH level is sensitive to the pituitary thyroid status but is not necessarily related to thyroid status in peripheral target tissues. In addition, the type 2 deiodinase, which controls the intracellular availability of T 3 in target cells, is regulated by substrate concentration: when T 4 availability is high, the enzyme activity is reduced and vice versa. This represents a local control mechanism that can be 'set' to optimise the intracellular T 3 concentration in a particular target cell (9) . These issues suggest: i) that serum hormone levels do not reflect tissue levels; ii) fT 4 is much more likely than TSH to be an indicator of tissue thyroid hormone responsiveness; and iii) small variations in fT 4 over a long period of time may have detrimental consequences including important effects on bone mineral density (BMD), the cardiovascular and CNS and the metabolic syndrome.
Apart from co-morbid disorders resulting in nonthyroidal illness, it is unclear whether symptoms or biological effects ascribed to subclinical hyper-or hypothyroidism are related to fT 4 levels in the upper or lower limits of the normal range rather than to decreased or increased TSH concentrations. Only a few studies have investigated a possible effect of the fT 4 concentration in subclinical thyroid dysfunction (10, 11, 12) , which by definition lies within the reference range. Moreover, it is possible that the subjects with subclinical hyperthyroidism and a fT 4 level in the upper normal range have more adverse clinical outcomes than the subjects with subclinical hyperthyroidism and fT 4 levels in the middle or lower reference range, or compared with euthyroid individuals (3). It is important, therefore, to determine whether the fT 4 concentration or the TSH level in subclinical thyroid disease is related to adverse long-term consequences in the target organs such as the skeleton.
Studies of BMD in euthyroid populations indicate that thyroid hormone regulates bone turnover (1, 5, 6, 13, 14, 15) . Murphy et al. (10) showed that low BMD in a euthyroid population of postmenopausal women was associated with fT 4 and free T 3 (fT 3 ) levels but not with TSH. These findings were supported by extensive data on mutant mice and other animals (16) . In Nicholls' recent review, the authors highlight that the HPT axis setpoint at the upper end of the reference range is associated with reduced BMD and increased susceptibility to fracture, and discuss whether fT 4 is the predominant determinant of the skeletal response to altered thyroid status (13) . They concluded that the HPT axis setpoint should be considered as a whole and that, because of the reciprocal relationship between T 4 and TSH, it is difficult determine whether high/normal fT 4 or low/normal TSH is the major determinant.
In the current study, we investigated BMD in perimenopausal women with: i) low or undetectable serum TSH levels irrespective of where the fT 4 concentration lies within the reference range; ii) low or undetectable serum TSH levels and fT 4 levels in the highest quartile of the reference range; iii) low or undetectable serum TSH levels and fT 4 in the lower three quartiles of the reference range; and iv) euthyroidism.
Subjects and methods

Participants
Subjects were part of the Eindhoven Perimenopausal Osteoporosis Study (EPOS) cohort described previously (17, 18) . All women born between 1941 and 1947 (nZ8503) in Eindhoven, The Netherlands, were invited for the measurement of BMD (17) . A total of 6846 women (78%) gave their consent and data on menstrual, gynaecological and medical history (including prior and family history of thyroid dysfunction, osteoporosis and fracture) and life style (smoking, alcohol and BMI) were also collected. Blood samples were collected and stored at K80 8C. Subsequently, a cohort of 2584 women was randomly selected for the assessment of thyroid function (TSH, fT 4 and thyroid peroxidase antibody (TPO-Ab)) (18) (Fig. 1) .
Exclusion criteria included the following ( Fig. 1 ): women receiving thyroid (nZ67) or osteoporosis (nZ13) medication or hormone replacement therapy (nZ596), with a previous history of thyroid dysfunction (nZ236), with elevated titres of TPO-Ab (nZ245; many women receiving T 4 were also TPO-Ab-positive) or with a prior history of bilateral oophorectomy (nZ78). Therefore, 1489 peri-menopausal (i.e. premenopausal, normal menstruation pattern; menopausal, irregular menstruation pattern or postmenopausal, O2 years after last menstruation) women were included (Table 1) .
This study was approved by the Medical Ethics Committee, Maxima Medical Centre of Veldhoven Hospital and written informed consent was obtained from all participants.
8-26 pmol/l; Abbott) and TPO-Ab (Cambridge Life Sciences, Cambridge, UK). A non-fasting venous blood sample was drawn from all participants. Coefficients of variation for fT 4 were 6.8, 8.2 and 6.7% at concentrations of 6.4, 18 and 30 pmol/l respectively; for TSH 9.8, 4.8, 3.9 and 3.1% at the concentrations of 0.06, 0.75, 6.8 and 30 mU/l respectively; and for TPO-Ab 9.6% at a concentration of 231 U/ml (17). A TPO-Ab level O100 U/ml was defined as positive (18) .
Bone mineral density
BMD was measured at the lumbar spine (L1-L4) by dualenergy X-ray absorptiometry (S.A. Hologic Europe, Brussels, Belgium) as described (17) . Osteopenia is defined as a BMD 1-2.5 S.D. below the young adult mean (T-score). T-score values !2.5 S.D. are defined as osteoporosis (19) . According to Hologic reference data, the mean (CS.D.) BMD at L1-L4 in 650 healthy women studied at the University of San Diego was 1.047C0.110 g/cm 2 . Osteopenia is therefore defined as a value between 0.937 and 0.772 g/cm 2 , and osteoporosis as a value below 0.772 g/cm 2 . The mean BMD of 232 premenopausal women in this study was 1.056G 0.123 g/cm 
Statistical analysis
Analyses were performed using Statistical Products and Service Solutions Software (SPSS-19, IBM). BMD data were normally distributed and the differences between groups were analysed by c 2 and Student's t-tests. Quartiles of logTSH and fT 4 were calculated and the differences in mean BMD and prevalence of osteopenia were analysed using ANOVA and c
2
. Effect sizes were calculated according to Cohen, and coefficients below 0.32, between 0.33-0.55 and O0.55 are regarded as small, medium and large, respectively, with medium and large effect sizes being clinically relevant (20) . Multiple logistic regression (OR, 95% CI) was performed with low BMD as a dependent variable and low TSH (lowest quartile) and high fT 4 (highest quartile) as independent variables adjusted for BMI, age, smoking and alcohol intake. Power calculations were performed to determine adequacy of cohort size. Using a significance threshold (a) of 0.05 and power (1Kb) of 0.80, a sample size of 1026 subjects would be sufficient to detect a 10% difference in prevalence of low BMD between women with or without fT 4 in the highest quartile. Using the same parameters to model multiple linear regression analyses, a sample size between 1057 and 172 is required for 80% power to identify a Cohen's effect size coefficient (d) between 0.2 (small) and 0.5 (medium) at a significance level of P!0.05 (21) . These calculations indicate that the analysis of the final cohort of 1477 subjects is adequate.
Results
Two women with thyroid dysfunction, five women with fT 4 concentrations outside the reference range and five Pre-, peri-and postmenopausal women n=1489 Figure 1 Flow chart of the study population.
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Clinical Study L E van Rijn and others Low BMD related to fT 4 in peri-menopausal women 170:3women with subclinical hypothyroidism were excluded from the analysis ( Table 2 shows quartiles for logTSH and fT 4 in 1426 euthyroid women with normal TSH and fT 4 . Low logTSH was defined as a value in the lowest quartile (!0.032 mU/l) and high fT 4 was defined as value in the highest quartile (O16.7 pmol/l). When mean BMD was compared among quartiles of logTSH concentration, no difference was identified (FZ1.4, PZ0.24). There was, however, a significant difference in mean BMD among quartiles of fT 4 (Table 2 , FZ3.9, PZ0.009). Post-hoc analysis indicated the highest quartile differed significantly from the lower three quartiles. In Fig. 2 , the percentage of women with low BMD in each logTSH quartile is shown; the prevalence of low BMD was 33% in the lowest quartile and 29% in the highest quartile (c 2 Z6.4, dfZ3, PZ0.10). The prevalence of low BMD (osteopenia) among fT 4 quartiles excluding women with low or undetectable serum TSH levels is shown in Fig. 3 .
The prevalence of osteopenia was 30% in the lower three quartiles but was higher at 40% in the upper fT 4 quartile (c 2 Z9.2, dfZ3, PZ0.027, effect size: wZ0.35). In 51 women with low or undetectable serum TSH levels, 39% had fT 4 concentrations in the highest quartile (Group II) and 61% had fT 4 levels in the three lower quartiles (Group III). The mean BMD in women in Group II was 0.979 g/cm 2 , compared with 0.987 g/cm 2 in Group III.
The number of women with low BMD in Group II was 7 (35%) compared with 10 (32%) in Group III. 
Osteopenia and osteoporosis in relation to thyroid function
Of the total number of 1477 women, 978 had normal BMD, 420 had osteopenia and 77 had osteoporosis. In the subgroup of women with fT 4 in the highest quartile, 217 had normal BMD, 121 had osteopenia and 27 had osteoporosis, which was significantly different (c 2 Z11.1, dfZ2, PZ0.004, effect size: wZ0.59). In women with logTSH in the lowest quartile, there was no difference in proportions of women with normal BMD, osteopenia and osteoporosis (c 2 Z0.27, dfZ2, PZ0.87). Furthermore, the mean fT 4 concentrations differed in women with normal BMD, osteopenia and osteoporosis (15.4, 15.8 and 16.9 pmol/l respectively (FZ3.4, PZ0.03)), whereas there were no differences in mean logTSH concentrations between the subgroups.
Independent relation between thyroid function and BMD
Subsequently, multiple logistic regression analysis was performed (Table 3) , adjusting for age, smoking, BMI and alcohol intake. There were 32 women (2.1%) using a betablocking drug which might interfere with thyroid function. Therefore, we also adjusted for beta-blocking drug intake.
As can be seen in Table 3 , low BMI, higher age, smoking and fT 4 in the highest quartile were independently related to low BMD (OR, 1.53; 95% CI, 1.11-2.10), but there was no relationship between low BMD and low logTSH (Table 3) or beta-blocking agents intake. When data were analysed by multivariate linear regression (Table 4) including BMD as continuous dependent variable, a similar model was found (FZ22, P!0.001, rZ0.31, effect size: 0.68), with higher age, smoking, low BMI and fT 4 in the highest quartile predicting low BMD with no effect of low logTSH or beta-blocking agents.
Discussion
This study demonstrates that higher fT 4 concentrations within the physiological reference range are independently related to low BMD in peri-menopausal women. There was no relationship between TSH concentration and BMD. The lack of association between low TSH and low BMD even in individuals with low or undetectable serum TSH levels is likely to be because only 39% of these women also had fT 4 levels in the upper quartile of the reference range.
The characteristics of the cohort investigated in the current study are similar to the original total EPOS population (17) . The fact that so few women with low or undetectable serum TSH levels were present is because TPO-Ab-positive women, who are well known to be at particular risk for developing subclinical and overt hypothyroidism, were excluded (1). The finding that higher age, low BMI and smoking were independently related to low BMD is in accordance with previous reports (22, 23, 24) .
The strength of the current study is that all participants were peri-menopausal women within a narrow age range (11 years) and they were not receiving hormone replacement therapy or osteoporosis medication. Moreover, women with previous thyroid disease, on thyroid medication and at risk of thyroid dysfunction (TPO-Ab-positive) were excluded. High TPO-Ab titers are associated with higher TSH and lower fT 4 levels. In the excluded 245 TPO-Ab-positive women (10% of the 
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original cohort in which thyroid parameters were assessed, which is consistent with previous data (3)), TSH was significantly higher and fT 4 was significantly lower compared with TPO-Ab-negative women (P!0.001, Mann-Whitney U test). However, most women with elevated TPO-Ab titers are not recognized and if such women had been included, their thyroid function could have affected BMD. Nevertheless, TSH did not correlate with BMD, whereas fT 4 was weakly but significantly inversely correlated with BMD. According to Cohen's coefficient, the effect size of this correlation (rZ0.06, effect sizeZ0.18) was below 0.33, which is considered to indicate a moderate clinically relevant effect size (20) . Further analysis revealed that when fT 4 concentration was grouped by quartiles, only the highest quartile included a significantly higher proportion of women with osteopenia or osteoporosis whereas each of the lower three quartiles had a similar prevalence of low BMD. Murphy et al. (10) similarly demonstrated an independent relationship between fT 4 in the highest quintile of the reference range and low BMD in healthy euthyroid postmenopausal women, and they also found no relationship between TSH and BMD. When we analysed the current data using quintiles of fT 4 , we found an even higher independent effect of fT 4 in the upper normal range (1.35, 95% CI, 1.02-1.79, PZ0.036). Similar to the current study, Murphy et al. also reported an inverse correlation between fT 4 and BMD by multiple linear regression. Other studies have also demonstrated that women with higher fT 4 levels within the normal reference range have lower BMD, but they found little or no association between BMD and TSH (10, 11, 12, 25) . Interestingly, in a study from Taiwan using a similar cross-sectional design in women of comparable age to the current study, no relation was demonstrated between TSH and BMD, while the authors found a significant but weak correlation between BMD and fT 4 in postmenopausal women (11) . However, because of the inverse relationship between TSH and T 4 that results from negative feedback regulation of the HPT axis (as reviewed elsewhere (5, 10)), it is not possible to make a distinction between the physiological importance of higher fT 4 levels compared with lower TSH levels.
Importantly, the current work and other related studies are associated studies and therefore cannot demonstrate causal relationships between either fT 4 or TSH with BMD. As noted above, such studies are not able to ascribe specific and independent roles for either hormone in the regulation of bone density because of their physiological reciprocal relationship as defined by the HPT axis. A recent review of the literature showed evidence that for both 'endogenous' as well as 'exogenous' subclinical hyperthyroidism, postmenopausal women rather than premenopausal women are at increased risk for lower BMD (26) . However, most if not all of the studies considered in this review failed to discriminate women with subclinical hyperthyroidism and fT 4 levels at the upper normal range from those with fT 4 levels at the lower normal range. It should be noted in the current study that women with endogenous (with elevated TPO-Ab titres) and exogenous (receiving hormone replacement therapy) subclinical hyperthyroidism were excluded from the analysis. Overall, our data indicate an inverse relation between fT 4 at the upper end of the reference range and BMD.
It is well established that thyroid hormones, acting via TRa, promote catabolic actions on the adult skeleton (6) . In hyperthyroidism, bone resorption and formation are both accelerated and the remodelling cycle is shortened. Furthermore, TRb K/K mice display osteoporosis despite elevated (27) . All these observations are consistent with the outcome of the current study, which demonstrates that higher fT 4 levels, but not lower TSH concentrations, are related to reduced BMD. Nevertheless, TSH receptor expression has been documented in skeletal cells (28) , although the clinical importance of this finding remains controversial. However, if TSHR expression is regulated by T 3 in skeletal cells then such a local regulatory mechanism could account for complex interplay between thyroid hormones and TSH regulation. Such a possibility could support measurement of both fT 3 and fT 4 as well as TSH in future studies, although the T 3 level in target tissues does not necessarily correlate well with its circulating concentration.
Several limitations of the study should be considered. First, a cross-sectional design was used and it was not possible to determine whether there is a relationship between fT 4 or TSH and loss of BMD or incident fracture. Second, BMD was only assessed at the lumbar spine and not at the hip or other anatomical sites. However, there is no evidence that effects of T 4 on BMD are restricted to the vertebrae: indeed, Murphy et al. showed that high fT 4 was related to low BMD at both the lumbar spine and hip (10) . Third, only fT 4 and not fT 3 levels were assessed and bone markers were not evaluated. In addition, only a single measurement of T 4 and TSH was available; this reduces precision, but the size of the well-characterised cohort and power of the study mitigate these issues. Fourth, the Hologic thresholds for low BMD were based on a USA population, which is of different ethnic origin to the current study that contains predominantly white European Caucasian women. Finally, the presence of non-thyroidal illness was not defined as a specific exclusion criterion; some chronic conditions that cause non-thyroidal illness may also interfere with BMD and thus confound the reported findings, although the large size of the population also mitigates this potential problem. What is the clinical relevance of the current study? There is consensus that the consequences of subclinical thyroid dysfunction on symptoms and adverse clinical outcomes are minimal, although the precise outcomes of studies are variable (1, 3, 4) . Most if not all studies do not take account of the fT 4 level in individuals with subclinical hyperthyroidism. By definition, women with a decreased TSH and fT 4 level in the lower reference range are categorised in the same group as women with a decreased TSH but fT 4 level in the upper reference range. In light of the current findings, it is likely that failure to account for differences in the fT 4 concentration in women with low or undetectable serum TSH levels explains the inconclusive findings of previous studies.
We suggest that inclusion of fT 4 level when evaluating a possible relationship between subclinical hyperthyroidism and BMD or between low or undetectable serum TSH levels and BMD would better appreciate the HPT axis setpoint. Both the HPT axis setpoint and BMD are continuous parameters and extremes of their normal reference ranges represent variations of normal that may result in long-term metabolic risk. Such consideration is consistent with the concept that there is a physiological trade-off between the HPT axis setpoint and BMD. We favour the interpretation that the combination of thyroid hormones and TSH should be considered responsible for the effect on BMD because i) studies cannot discriminate between the two because of their physiological inverse relationship and ii) no studies have been designed to address this point specifically in a discriminatory way.
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